| Literature DB >> 31236408 |
Violeta Corina Cristea1,2, Irina Gheorghe3,4, Ilda Czobor Barbu3,4, Laura Ioana Popa3,4, Bogdan Ispas3,4, Georgiana Alexandra Grigore3,4, Irina Bucatariu3,4, Gabriela Loredana Popa2, Maria-Cristina Angelescu1, Alexandra Velican3,4, Luminita Marutescu3,4, Marcela Popa3,4, Mariana Carmen Chifiriuc3,4, Ioan Mircea Popa2,5.
Abstract
BACKGROUND: Urinary tract infections (UTIs) caused by Uropathogenic Escherichia coli (UPEC) are among the most common infections worldwide, including Romania. To the best of our knowledge, this is the first study performed on a significant number of community-acquired (CA) UPEC strains isolated from Romanian outpatients, aiming to evaluate and establish potential correlations among the phylogenetic groups (PG), resistance profiles, and the virulence factors (VF) genes of the CA-UPEC isolates. MATERIALS/Entities:
Mesh:
Substances:
Year: 2019 PMID: 31236408 PMCID: PMC6545812 DOI: 10.1155/2019/5712371
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Antibiotic resistance phenotypes of E. coli strains isolated from CA-UTIs in Romania.
| Antibiotic | GR A | GR B1 | GR B2 | GR D | Number (percentage) |
|---|---|---|---|---|---|
| AMP | 90 (52.94%) | 98 (45.16%) | 125 (45.28%) | 66 (53.65%) | 374 (47.52%) |
| TET | 75 (44.11%) | 91 (41.93%) | 98 (35.50%) | 61 (49.59%) | 324 (41.16%) |
| SXT | 43 (25.29%) | 52 (23.96%) | 60 (21.73%) | 41 (33.33%) | 192 (24.39%) |
| AMC | 38 (22.35%) | 41 (18.89%) | 55 (19.92%) | 24 (19.51%) | 151 (19.18%) |
| CFZ | 35 (20.58%) | 29 (13.36%) | 42 (15.21%) | 17 (13.82%) | 122 (15.50%) |
| CIP | 34 (20%) | 38 (17.51%) | 28 (10.14%) | 18 (14.63%) | 118 (14.99%) |
| LEV | 34 (20%) | 38 (17.51%) | 28 (10.14%) | 18 (14.63%) | 117 (14.86%) |
| ATM | 16 (9.41%) | 21 (9.67%) | 27 (9.78%) | 11 (8.94%) | 79 (10.03%) |
| FEP | 16 (9.41%) | 21 (9.67%) | 26 (9.42%) | 10 (8.13%) | 73 (9.27%) |
| CRO | 16 (9.41%) | 21 (9.67%) | 26 (9.42%) | 10 (8.13%) | 72 (9.14%) |
| TZP | 17 (10%) | 11 (5.06%) | 16 (5.79%) | 3 (2.43%) | 47 (5.97%) |
| CN | 12 (7.05) | 6 (2.76%) | 10 (3.62%) | 7 (5.69%) | 34 (4.32%) |
| NIT | 5 (2.94%) | 8 (3.68%) | 7 (2.53%) | 4 (3.25%) | 24 (3.04%) |
| IMP | 0 | 0 | 0 | 1 (0.81%) | 1 (0.12%) |
| MEM | 0 | 0 | 0 | 0 | 0 |
| ETP | 0 | 0 | 0 | 0 | 0 |
AMP, ampicillin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; AMC, amoxicillin-clavulanic acid; CFZ, cefazolin; CIP, ciprofloxacin; LEV, levofloxacin; ATM, aztreonam; FEP, cefepime; CRO, ceftriaxone; TZP, piperacillin-tazobactam; CN, gentamicin; NIT, nitrofurantoin; IMP, imipenem; MEM, meropenem; ETP, ertapenem.
Antibiotic resistance phenotypes of ESBL strains.
| Antibiotic | Number (percentage) |
|---|---|
| AMP | 71 (100%) |
| ATM | 70 (98.59%) |
| FEP | 70 (98.59%) |
| CRO | 65 (91.59%) |
| CFZ | 62 (87.32%) |
| TET | 52 (73.23%) |
| CIP | 51 (71.83%) |
| LEV | 50 (70.42%) |
| SXT | 34 (47.89%) |
| AMC | 32 (45.07%) |
| TZP | 17 (23.94%) |
| NIT | 6 (8.45%) |
Figure 1The distribution of ESBL and MDR isolates by phylogenetic groups.
The association of different VF genes with PGs.
| GR A | GR B1 | GR B2 | GR D | p-value | |
|---|---|---|---|---|---|
|
| 155 (91.17%) | 204 (94%) | 264 (95.65%) | 116 (94.30%) | 0.2873 |
|
| 51 (30%) | 72 (33.17%) | 118 (42.75%) | 51 (41.46%) | 0.0196 |
|
| 1 (0.58%) | 3 (1.38%) | 7 (2.53%) | 25 (20.32%) | 0.0693 |
|
| 21 (12.35%) | 43 (19.81%) | 69 (25%) | 14 (11.38%) | 0.0010 |
|
| 12 (7.05%) | 72 (33.17%) | 96 (34.78%) | 13 (10.56%) | <0.0001 |
|
| 13 (7.64%) | 42 (19.35%) | 127 (46.01%) | 9 (7.31%) | <0.0001 |
|
| 2 (1.17%) | 13 (5.99%) | 32 (11.59%) | 6 (4.87%) | 0.0005 |
Figure 2The distribution of VFs by PGs.
Figure 3The distribution of the number of VFs among PGs.
Virulence genes profiles and PGs in the investigated E. coli strains.
| VF | Number (percentage) |
|---|---|
|
| 739 (93.90%) |
|
| 349 (44.34%) |
|
| 301 (38.24%) |
|
| 257 (32.65%) |
|
| 188 (23.88%) |
|
| 98 (12.45%) |
|
| 61 (7.75%) |
|
| |
|
| 276 (35%) |
|
| 216 (27%) |
|
| 173 (22%) |
|
| 122 (16%) |
Primers sequences used in simplex and multiplex PCR assays for genes encoding BLSE.
| The gene | Primer | Nucleotide sequence | Amplification size | References |
|---|---|---|---|---|
|
| TEM-F | 5'-ATGAGTTTTCAACATTTTCG-3' | 861 | Eftekar et al., 2005 [ |
|
| ||||
|
| SHV-F | 5'-GCCCTCACTCAAGGATGTAT-3' | 888 | Naas et al., 1999 [ |
|
| ||||
|
| CTX-M-F | 5'-CGCTGTTGTTAGGAAGTGTG-3' | 730 | Israil et al., 2013 [ |
Table 5 is partially reproduced from Grosu et al. 2017 [underthe Creative Commons Attribution License/public domain].
Primers sequences used in simplex and multiplex PCR assays for virulence genes.
| The gene | Primer | Amplification size and | References |
|---|---|---|---|
|
| F: 5′-GACGAACCAACGGTCAGGAT-3′ | 279 bp | Clermont et al., 2000 |
|
| |||
|
| F: 5′-TGAAGTGTCAGGAGACGCTG-3′ | 211bp | Clermont et al., 2000 |
|
| |||
|
| F: 5′-GAGTAATGTCGGGGCATTCA-3′ | 152 bp (multiplex) | Clermont et al., 2000 |
|
| |||
|
| F: 5′- CTCCGGTACGTGAAAAGGAC-3′ | 904 bp | Rodrigues-Sike et al., 2005 |
|
| |||
|
| F: 5′- GCG CAT TTG CTG ATA CTG TTG-3′ | 272 bp | Johnson et al., 2005 [ |
|
| |||
|
| F:5′-AACAAGGATAAGCACTGT TCTGGC T-3′ | 1,177 bp | Yamamoto et al., 1995 [ |
|
| |||
|
| F:5′-CGGAGGAGTAATTACAAACCTGGCA -3′ | 408 bp | Blanco et al., 1997 [ |
|
| |||
|
| F: 5′-TGC AGA ACG GAT AAG CCG TGG -3′ | 508 bp | Rodrigues-Sike et al., 2005 |
|
| |||
|
| F: 5′-GCTGGGCAGCAAACTGATAACTCTC -3′ | 793 bp | Blanco et al., 1997 |
|
| |||
|
| F: 5′- GAA CTT ATT AAG GAT AGT-3′ | 543kb | Blanco et al., 1997 |
Table 6 is reproduced from Grosu et al. 2017 [under the Creative Commons Attribution License/public domain].